SCHEMBL3010388

SCHEMBL3010388

O=S(=O)(c1c(F)c(F)c(F)c(F)c1F)N1CCN(c2nc(-c3cccc(Br)c3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
HSD17B10 Q99714 2/20 0.56
USP2 O75604 1/20 0.56
RECQL P46063 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.54
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
LMNA P02545 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPK1 P28482 4/20 0.52
AR P10275 3/20 0.43
RAB9A P51151 4/20 0.43
HPGD P15428 1/20 0.43
HK1 P19367 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
GBA1 P04062 1/20 0.43
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42
CDC25A P30304 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003526 0.92 MAPT (0.56) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL2998245 0.88 MAPT (0.51) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3015420 0.88 MAPT (0.59) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL2998664 0.87 LMNA (0.68) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3006787 0.87 ALDH1A1 (0.74) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3010391 0.86 MAPT (0.59) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3650189 0.86 MEN1 (0.53) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3019267 0.86 LMNA (0.53) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3008318 0.86 MAPT (0.62) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3011030 0.85 MAPT (0.63) MAPTHSD17B10USP2RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.